Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

15 maggio 2022 Senza categoria
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento